GeneMedix cash running low as complexities delay restructuring

GeneMedix plc (GMX.L) today effectively set itself a two month deadline to complete critical parts of its restructuring when it announced an operating loss of £1.3m for the quarter to end February.

The UK-based biopharmaceutical with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings said it believed there is enough finance available to take it through its restructuring period first announced in October.

GeneMedix is involved in the development and manufacture of therapeutic proteins using recombinant DNA technology and novel cell culture.

Acting CEO Julian Attfield (pictured) said "We have good prospects of receiving cash on the sale of our Chinese facility within a short timeframe, with total proceeds of approximately £1.6m being secured within a few months. It is also our intention to secure bridging finance at a time that we announce exclusivity with one party in our restructuring".

But he warned that "We must be clear, that, without achieving such cash inflows we only have sufficient resources to continue our current level of activity for a maximum of two months from [today]."

The company's share price shed 7.4%, or 0.25p to 3.13p on the news. It is now valued at £11.9m.

At the end of March, the company said it planned to complete the restructuring "over the coming few weeks".

Today Mr Attfield said: "We are aware that the restructuring process has taken longer than originally anticipated, but this is due to us operating in a complex technical and regulatory environment, which requires an extended and rigorous due diligence process on both sides of any transaction."

In talks

He said the company was in late stage negotiations with a number of parties. In the meantime it had continued to exercise prudent cost control and the development of its biosimilar erythropoietin (EPO) programme continued to show excellent results.

There were no revenues in the period.

The company reported in March that the Directors have known for a significant time that there has been a need through a transforming M&A transaction to enhance the infrastructure and product offering of the company.

"The real strengths of the company are the portfolio of EPO, Interferon-alfa and the lesser developed G-CSF, in combination with our quality manufacturing facility in Tullamore, Ireland, and highly experienced development, manufacturing and regulatory teams," Mr Attfield said back then.

30th May 2006

Previous articles
Plastic Logic closes in on pilot production for 'disruptive' high-res plastic e-readers
Screen Technology partners with Wilden AG; boosts cash position
Snippets: Aveva in £4m customer deal: Cisco invests in ip.access
ANT has good revenue gains in ’09; losses narrow: profitable in 2H
Prelude Trust’s asset value unchanged in 06/07; but portfolio companies’ revenue grows 300%
CSR turns in record Q3 results but says Q4 sales will be lower
Briefs: Autonomy signs $20m deal; University investigates Web 3.0 for learning tools
ARM Holdings results hit by weak dollar; share price sheds 12%: but has high order backlog
Biotech Lumora secures licensing deal with bioMérieux
Autonomy launches iPhone app for legal eagles
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • CSR


Joep van Beurden
Chief Executive Officer


CSR plc is the leading global provider of Bluetooth technology and has developed expertise in other single-chip wireless communication standards such as Wi-Fi (IEEE802.11). CSR offers developed hardware/software solutions for Bluetooth based around BlueCore, a fully integrated 2.4 GHz radio, baseband

[CSR's profile]


Top20 Index




Currently: 131.89

Best Rate Mortgages
Click here to use experts’ free mortgage advice and find the best rate mortgages.

Marcus Evans conferences
See how Marcus Evans' clients have hugely developed their company's existing strategies!

Scam events for Marcus Evans
Attend anti scam events for Marcus Evans and find out how to manage internal company investigations.

IFM
IFM’s integrated ferrochrome mining and production facilities use the latest technology.